Peptide Database

Browse Research Peptides

Comprehensive profiles for 105+ peptides — dosing protocols, mechanisms of action, clinical research, and safety data.

105

Peptides

9

Categories

105 peptides · page 1 of 5

Weight LossPreclinical

5-Amino-1MQ

5-amino-1-methylquinolinium

A selective NNMT (nicotinamide N-methyltransferase) inhibitor that enhances cellular energy metabolism. Not technically a peptide but a small molecule research compound. Mouse studies showed 30%+ decrease in adipocyte size.

Animal Studies50-75 mg daily
HormonalNot FDA Approved

ACE-031

ACVR2B-Fc

A fusion protein combining the activin IIB receptor with antibody Fc domain. Phase II trials in Duchenne MD showed significant muscle mass increase but were halted due to nosebleeds and gum bleeding.

Animal Studies0.5-3 mg/kg every 2 weeks (from discontinued trials)
Skin & HairNot FDA Approved

AHK-Cu

Tripeptide-3

A copper-binding tripeptide primarily used for hair growth stimulation. Shows promise for both hair loss prevention and scalp health.

CommunityTopical scalp serums and solutions
Weight LossIn Clinical Trials

AOD-9604

Anti-Obesity Drug 9604

A modified fragment of human growth hormone (amino acids 177-191) studied for fat metabolism effects without the broader hormonal effects of full GH.

Clinical Trials300 mcg daily
CognitiveIn Clinical Trials

ARA-290

Cibinetide

An 11-amino acid peptide derived from erythropoietin (EPO) that selectively activates the innate repair receptor. No erythropoietic effects.

Clinical Trials4 mg daily
HormonalFDA Approved

Abaloparatide

Tymlos

A PTHrP analog that stimulates bone formation with potentially fewer side effects than teriparatide. Represents a newer anabolic option for osteoporosis management.

FDA Approved80 mcg daily
Skin & HairNot FDA Approved

Argireline

Acetyl Hexapeptide-3

A popular cosmetic peptide that reduces facial wrinkles by inhibiting neurotransmitter release. Studies show 30% reduction in wrinkle depth after 30 days.

Community5-10% concentration in formulations
HealingPreclinical

BPC-157

Body Protection Compound-157

A synthetic peptide derived from a protein found in human gastric juice. Extensive preclinical studies demonstrate efficacy in healing tendons, ligaments, muscles, and the GI tract.

Animal Studies250-500 mcg twice daily
HormonalFDA Approved

Bivalirudin

Angiomax

A synthetic direct thrombin inhibitor derived from hirudin used as an anticoagulant during percutaneous coronary intervention procedures.

FDA Approved0.75 mg/kg IV bolus; 1.75 mg/kg/h infusion
BioregulatorPreclinical

Bronchogen

Ala-Glu-Asp-Leu

A tetrapeptide bioregulator from the Khavinson family designed to support respiratory tissue and bronchial health through tissue-specific gene regulation.

Animal Studies10-20 mg daily
Growth HormoneIn Clinical Trials

CJC-1295

CJC-1295 no DAC

A synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates GH release from the pituitary.

Clinical Trials100 mcg daily (no DAC)
Growth HormoneNot FDA Approved

CJC-1295 DAC

Modified GRF 1-29 DAC

CJC-1295 variant containing a reactive linker that binds to albumin after injection, extending half-life from minutes to 6-8 days for sustained GHRH stimulation.

Clinical Trials1-2 mg weekly
Weight LossNot FDA Approved

CagriSema

Semaglutide + Cagrilintide

Investigational combination therapy demonstrating 22.7% body weight reduction at 68 weeks in Phase 3 trials, outperforming semaglutide monotherapy.

Clinical TrialsSemaglutide 2.4mg + Cagrilintide 2.4mg weekly
Weight LossNot FDA Approved

Cagrilintide

AM833

Long-acting amylin analog for obesity treatment operating through distinct pathways compared to GLP-1 agonists. Phase 3: 11.8% weight loss (monotherapy); 20.4% (CagriSema combination).

Clinical Trials2.4 mg weekly
HormonalFDA Approved

Calcitonin

Miacalcin

A thyroid hormone that inhibits bone resorption. Salmon calcitonin demonstrates 40-50x greater potency than human forms.

FDA Approved200 IU intranasal daily or 100 IU SC/IM daily
BioregulatorNot FDA Approved

Cartalax

Ala-Glu-Asp

A synthetic tripeptide designed for joint tissue support and regeneration. Russian studies demonstrate cartilage protective effects.

Animal Studies10-20 mg daily
CognitiveNot FDA Approved

Cerebrolysin

FPE 1070

A neuropeptide mixture derived from porcine brain tissue, indicated for neurological conditions including stroke recovery, cognitive decline, and traumatic brain injury.

Clinical Trials5-10 mL IV/IM daily for 10-20 days
BioregulatorPreclinical

Chonluten

Glu-Asp-Gly

A tripeptide bioregulator targeting respiratory and lung tissue. Supports healthy lung function and stomach lining.

Animal Studies10-20 mg daily
BioregulatorPreclinical

Cortagen

Ala-Glu-Asp-Pro

A tetrapeptide bioregulator (Ala-Glu-Asp-Pro) derived from cerebral cortex extracts. Studied for neuroprotection, neural differentiation, and cognitive support.

Animal Studies10-20 mg daily
HormonalFDA Approved

Cosyntropin

Cortrosyn

A synthetic fragment of ACTH used to diagnose adrenal insufficiency. The standard test for evaluating adrenal function. Contains the first 24 amino acids of ACTH.

FDA Approved250 mcg IV/IM (standard) or 1 mcg IV (low-dose)
BioregulatorPreclinical

Crystagen

Glu-Asp-Pro

A tripeptide bioregulator supporting immune system function. Demonstrates age-associated immunoprotective properties in spleen tissue.

Animal Studies10-20 mg daily
Anti-AgingNot FDA Approved

DSIP

Delta Sleep Inducing Peptide

A peptide studied for its ability to promote deep sleep and modulate stress hormones.

Clinical Trials100-250 mcg before bed
HormonalFDA Approved

Desmopressin

DDAVP

Synthetic vasopressin analog that selectively activates V2 receptors in kidneys, promoting water reabsorption.

FDA Approved10-40 mcg intranasal or 0.1-0.4 mg oral
CognitivePreclinical

Dihexa

N-hexanoic-Tyr-Ile-(6) aminohexanoic amide

A potent cognitive-enhancing peptide derived from angiotensin IV. Reported to be 10 million times more potent than BDNF at promoting synaptogenesis.

Animal Studies5-20 mg oral or sublingual daily